Monocyte chemoattractant protein-1 and cyclooxygenase enzymes in rats treated with drugs of abuse
DOI:
https://doi.org/10.56511/JIPBS.2024.11202Abstract
The CC chemokine monocyte chemoattractant protein (MCP)-1/CCL2 and cyclo-oxygenase-2 enzyme are potent mediators of neuroinflammation. We studied the effect of treatment with Cannabis sativa resin extract and/or tramadol, two common drugs of abuse on the level of MCP-1 in brain and serum of rats. In addition, serum levels of cyclo-oxygenase 1 (COX-1) and cyclo-oxygenase 2 (COX-2) enzymes in rats given cannabis were also determined. Cannabis sativa resin at 5, 10 or 20 mg/kg (expressed as delta-9-tetrahydrocannabinol), tramadol at 5, 10 or 20 mg/kg or tramadol at 10 mg/kg combined with cannabis at 5-20 mg/kg were given once a day, subcutaneously, for six weeks. Results showed that, as compared to corresponding controls, Cannabis sativa resin produced a significant increase in MCP-1 increased in brain tissue (29.8-56.4%) and serum (14.8-31.0%). MCP-1 showed also significant increments in brain (34.6%) and serum (22.1%) by 20 mg/kg tramadol. After the concomitant treatment with both cannabis and tramadol, MCP-1 increased in brain by 88.5-145.7% and in serum by 32.6-64.8%. Moreover, cannabis given at 20 mg/kg significantly increased serum COX-1 and COX-2 by 362% and 58.8% compared to corresponding control values. The histopathological study of the striatum of cannabis-treated animals revealed the presence of apoptotic cells and pyknotic nuclei and congestion of blood vessels. The striatum from animals given tramadol showed neuronal perinuclear cytoplasmic vacuolations and apoptotic cells. Moreover, the combined administration of both cannabis and tramadol resulted in neuronal necrosis, vacuolation, apoptosis and pyknosis. Collectively, these results indicate that treatment with cannabis resin and/or tramadol is associated with a proinflammatory response that involves MCP-1 and cyclooxygenases and which could result in the development of brain injury.
Keywords:
Tramadol, cannabis, addiction, monocyte chemoattractant protein, cyclooxygenaseDownloads
References
Market analysis of plant - based drugs - Opiates, cocaine, cannabis. United Nations Office on Drugs and Crime, World Drug Report. United Nations publication, Sales No. E.17.XI.9, Vienna, Austria, 2017; 37 - 45.
UNODC, World Drug Report 2023 (United Nations publication, 2023). Available at: www.unodc.org/unodc/en/data - and - analysis/world - drug - report - 2023.html.
Marilyn A. Huestis. Cannabis (marijuana) — effects on human behavior and performance. Forensic Sci Rev . 2002; 14:15.
Raphael Mechoulam, Yechiel Gaoni. The absolute configuration of delta - 1 - tetrahydrocannabinol, the major active constituent of hashish. Tetrahedron Lett . 1967; 12:1109 - 11.
Emilia Nocerino, Marianna Amato, Angelo A Izzo. Cannabis and cannabinoid receptors. Fitoterapia . 2000; 71: S6 - S12.
Fernando Rodríguez de Fonseca, Ignacio Del Arco, Francisco J Bermúdez - Silva, Ainhoa Bilbao Leis The endocannabinoid system: Physiology and pharmacology. Alcohol & Alcoholism . 2005; 40(1): 2 – 14.
Wayne Hal, Louisa Degenhardt. Adverse health effects of non - medical cannabis use. Lancet . 2009; 374 (9698): 1383 - 1391.
Nadia Solowij, Nicole Pesa. Cannabis and cognition: short and long term effects. In: David Castle, Robin M. Murray, Deepak Cyril D’Souza (eds). Marijuana and Madness, second Edn, New York, Cambridge University Press . 2012; 91 – 102.
Paola Casadio, Cathy Fernandes, Robin M. Murray, Marta Di Forti. Cannabis use in young people: The risk for schizophrenia. Neurosci. Biobehav. Rev. 2011: 35; 1779 – 1787.
David E. Mandelbaum, Suzanne M. de la Monte. Adverse structural and functional effects of marijuana on the brain: evidence reviewed. PediatrNeurol. 2017; 66:12 - 20.
Aoife Gowran, Veronica A. Campbell. A role for p53 in the regulation of lysosomal permeability by delta 9 - tetrahydrocannabinol in rat cortical neurones: implications for neurodegeneration. J. Neurochem. 2008; 105(4):1513 ‒ 24.
Omar M. E. Abdel - Salam, Eman Youness, Nermeen Shaffie. Biochemical, immunological, DNA and histopathological changes caused by Cannabis Sativa in the rat. J. Neurol. Epidemiol. 2014; 2: 6 - 16.
Karen Miotto, Arthur K. Cho, Mohamed A. Khalil, Kirsten Blanco, Jun D. Sasaki, Richard Rawson. Trends in tramadol: pharmacology, metabolism, and misuse. Anesth. Analg. 2017; 124(1):44 - 51.
Fatma M. Ghoneim, Hanaa A. Khalaf, Ayman Z. Elsamanoudy, Ahmed N. Helaly. Effect of chronic usage of tramadol on motor cerebral cortex and testicular tissues of adult male albino rats and the effect of its withdrawal: histological, immunohistochemical and biochemical study. Int. J. Clin. Exp. Patho. 2014; 7:7323 – 7341.
Ibrahim K. Ragab, Hala Z.E. Mohamed. Histological changes of the adult albino rats entorhinal cortex under the effect of tramadol administration: Histological and morphometric study. Alex. J. Med. 2017; 53 (2): 123 - 133.
Omar M. E. Abdel - Salam, Amany A. Sleem, Eman R. Youness, Enayat A. Omara. Identification of biomarkers for the detection of subtle brain injury after cannabis and/or tramadol administration. Egypt. J. Forensic. Sci. 2019; 9: 58.
Satish L. Deshmane, Sergey Kremlev, Shohreh Amini, Bassel E. Sawaya. Monocyte chemoattractant protein - 1 (MCP - 1): An overview. J. Interferon. Cytokine. Res. 2009; 29(6):313 - 26.
DeRen Huang, Jintang Wang, Pia Kivisakk, Barrett J. Rollins, Richard M. Ransohoff. Absence of monocyte chemoattractant protein - 1 in mice leads to decreased local macrophage recruitment and antigen - specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. J. Exp. Med. 2001; 193:713 – 26.
Paula Marie Hughes, Peter R. Allegrini, Markus Rudin, Victor Perry, Anis K. Mir, Christoph Wiessner. Monocyte chemoattractant protein - 1 deficiency is protective in a murine stroke model. J. Cereb. Blood. Flow. Metab. 2002; 22:308 – 17.
Yong Chen, John M. Hallenbeck, Christl Ruetzler, David Bol, Karen Thomas, Nancy E. J. Berman, Stefanie N. Vogel. Overexpression of monocyte chemoattractant protein 1 in the brain exacerbates ischemic brain injury and is associated with recruitment of inflammatory cells. J. Cereb. Blood. Flow. Metab. 2003; 23:748 – 755.
Wendy L. Thompson, William J. Karpus, Linda J. Van Eldik. MCP - 1 - deficient mice show reduced neuroinflammatory responses and increased peripheral inflammatory responses to peripheral endotoxin insult. J. Neuroinflammation 2008; 5:35.
Daniel E Furst. Pharmacology and efficacy of cyclooxygenase (COX) inhibitors. Am. J. Med. 1999; 107(6, Suppl.1): 18 - 22.
Luisa Minghetti . Cyclooxygenase - 2 (COX - 2) in inflammatory and degenerative brain diseases. J. Neuropathol. Exp. Neurol. 2004; 63 (9): 901 – 910.
Rosario Sanchez Pernaute, Andrew Ferree, Oliver Cooper, Meixiang Yu, Anna - Liisa Brownell, Ole Isacson. Selective COX - 2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. J. Neuroinflammation . 2004, 1:6.
Jocelyn C. Turner, Paul G. Mahlberg. Simple high - performance liquid chromatographic method for separating acidic and neutral cannabinoids in Cannabis sativa L. J. Chromatography . 1982; 253: 295 - 303.
Winston J. Fairbairn, Joel A. Liebman. The extraction and estimation of the cannabinoids in Cannabis sativa L. and its products. J. Pharm. Pharmac. 1973; 25: 150 - 155.
Teresa Iuvone, Giuseppe Esposito, Daniele De Filippis, Caterina Scuderi, Luca Steardo. Cannabidiol: a promising drug for neurodegenerative disorders? CNS. Neurosci. Ther. 2009;15(1):65 - 75.
Sandra Amor, Laura A.N. Peferoen, Daphne Y.S. Vogel, Marjolein Breur, Paul van der Valk, David Baker, Johannes M. van Noort. Inflammation in neurodegenerative diseases – an update. Immunology . 2014; 142(2):151 - 166.
Aurélie Joly - Amado, Jordan Hunter, Zainuddin Quadri, Frank Zamudio, Patricia V. Rocha - Rangel, Deanna Chan, et al. CCL2 overexpression in the brain promotes glial activation and accelerates tau pathology in a mouse model of tauopathy. Front. Immunol. 2020; 11:997.
Ada Bernaus, Sandra Blanco, Ana Sevilla. Glia crosstalk in neuroinflammatory diseases. Front Cell Neurosci . 2020; 14: 209.
Wei - Ju Lee, Yi - Chu Liao, Yen - Feng Wang, I - Feng Lin, Shuu - jiun Wang, Jong - Ling Fuh. Plasma MCP - 1 and cognitive decline in patients with Alzheimer’s disease and mild cognitive impairment: A two - year follow - up study. Sci. Rep. 2018; 8(1):1280.
Michael D. Rizzo, Robert B. Crawford, Anthony Bach, Sera Sermet, Andrea Amalfitano, Norbert E. Kaminski. Δ 9 - Tetrahydrocannabinol suppresses monocyte - mediated astrocyte production of MCP - 1 and IL - 6 in a TLR7 - stimulated human co - culture. J. Pharmacol. Exp. Ther. 2019; 371(1): 191 – 201.
Charles N. Zawatsky, Jasmina Abdalla, Resat Cinar. Synthetic cannabinoids induce acute lung inflammation via cannabinoid receptor 1 activation. ERJ. Open Res . 2020; 6: 00121 - 2020.
Jared Ehrhart, Demian Obregon, Takashi Mori, Huayan Hou, Nan Sun, Yun Bai, et al. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J. Neuroinflammation . 2005 ; 2:29.
Shin Fukuda, Hitoshi Kohsaka, Aiko Takayasu, Waka Yokoyama, Chie Miyabe, Yoshishige Miyabe, et al. Cannabinoid receptor 2 as a potential therapeutic target in rheumatoid arthritis. BMC. Musculoskelet. Disord. 2014; 15:275.
Frances Henshaw, Lauren Dewsbury, Chai K. Lim, Genevieve Z. Steiner - Lim. The effects of cannabinoids on pro - and anti - inflammatory cytokines: a systematic review of in vivo studies. Cannabis Cannabinoid. Res. 2021; 6(3) : 177 - 195.
Jonathon K. Lisano, Jacob N. Kisiolek, Peter Smoak, Kristina T. Phillips, Laura K. Stewart. Chronic cannabis use and circulating biomarkers of neural health, stress, and inflammation in physically active individuals. Appl. Physiol. Nutr. Metab. 2020; 45(3):258 - 263.
Michelle Sexton, Aurelio Silvestroni, Thomas Möller, Nephi Stella. Differential migratory properties of monocytes isolated from human subjects naïve and non - naïve to Cannabis. Inflammopharmacology . 2013; 21(3): 253 – 259.
Michelle Sexton, Eiron Cudaback, Rehab A. Abdullah, John Finnell, Laurie K. Mischley, Mary Rozga, et al. Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters. Inflammopharmacology . 2014; 22(5): 295 – 303.
Emilio Fernandez - Egea, Linda Scoriels, Swathi Theegala, Maria Giro, Susan E. Ozanne, Keith Burling, et al. Cannabis use is associated with increased CCL11 plasma levels in young healthy volunteers. Neuropsychopharmacol. Biol. Psychiatry. 2013; 46:25 - 8.
Sang - Ho Choi, Francesca Bosetti. Cyclooxygenase ‐ 1 null mice show reduced neuroinflammation in response to β‐ amyloid. Aging . 2009; 1(2) : 234 - 244.
Saba Aid, Robert Langenbach, Francesca Bosetti. Neuroinflammatory response to lipopolysaccharide is exacerbated in mice genetically deficient in cyclooxygenase -
J. Neuroinflammation. 2008; 5:17 – 30.
Sagnik Bhattacharyya. delta - 9 - tetrahydrocannabinol (THC) increases brain prostaglandins in the rat. Psychopharmacology (Berl) . 1986; 90(4):499 - 502.
Rongqing Chen, Jian Zhang, Ni Fan, Zhao - Qian Teng, Yan Wu, Hongwei Yang, et al. 9 - THC - caused synaptic and memory impairments are mediated through COX - 2 signaling. Cell . 2013;155: 1154 – 1165.
Wendy Swift, Alex Wong, Kong M. Li, Jonathon C. Arnold, Iain S. McGregor. Analysis of cannabis seizures in NSW, Australia: Cannabis potency and cannabinoid profile. PLoS ONE . 2013; 8(7): e70052.
Mahmoud A. ElSohly, Mohamed M. Radwan, Waseem Gul, Suman Chandra, Ahmed Galal. Phytochemistry of Cannabis sativa L. Prog. Chem. Org. Nat. Prod. 2017:103:1 - 36.
Roger Guy Pertwee, Adele Thomas, Lesley Ann Stevenson, Ruth Alexandra Ross, Stephen A. Varvel, Aron H Lichtman, et al. The psychoactive plant cannabinoid, 9 - tetrahydrocannabinol, is antagonized by 8 - and 9 - tetrahydrocannabivarin in mice in vivo. Br. J. Pharmacol. 2007; 150: 586 – 594.
Giuseppe Esposito, Caterina Scuderi, Marta Valenza, Giuseppina I. Togna, Valentina Latina Daniele De Filippis, et al. Cannabidiol reduces A β - induced neuroinflammation and promotes hippocampal neurogenesis through PPAR involvement. PLoS ONE . 2011; 6(12): e28668.
Agnese Gugliandolo, Federica Pollastro, Gianpaolo Grassi, Alessia Bramanti , Emanuela Mazzon. In vitro model of neuroinflammation: efficacy of cannabigerol, a non - psychoactive cannabinoid. Int J Mol Sci . 2018; 19 (7): 1992.
Omar M. E. Abdel - Salam, Amany A. Sleem, Eman R. Youness, Enayat A. Omara. Oxidative stress in brain tissue and serum of rats treated with cannabis resin, tramadol or both. ES. J. Neurol. 2020; 1(1): 1003.
Shimaa M. Azmy, Mai A. Abd Elo fattah, Sahar S. Abd El - Rahman, Somia A. Nada, Omar M.E. Abdel Salam, Mohammed F. El - Yamany, et al. Does nicotine impact tramadol abuse? Insights from neurochemical and neurobehavioral changes in mice . NeuroToxicology 2018; 67: 245 - 258.
Samy A. Hussein, Samir A. Abdel Aal, Hany K. Ismail. Effect of tramadol drug on some biochemical and immunological parameters in albino male rats; evaluation of possible reversal following its withdrawal. Benha Veterinary Medical. J. 2017; 33(2): 418 - 429.
Published
How to Cite
Issue
Section
Copyright (c) 2024 Omar M.E. Abdel-Salam, Eman R. Youness, Enayat A Omara, Amany A Sleem
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Journal of Innovations in Pharmaceutical and Biological Sciences is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Based on a work at